Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 22Phase 1/2 16Phase NA 12Phase EARLY_PHASE1 9Phase 3 5Phase 4 3Phase 2/3 3

Status

Completed 66Recruiting 25Unknown 22Active not recruiting 21Terminated 17Withdrawn 5Not yet recruiting 5

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 28Colorectal Neoplasms 16Neoplasms 13Nasopharyngeal Carcinoma 11Lung Neoplasms 10Leukemia, Myeloid, Acute 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Prostatic Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Rectal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Uterine Cervical Neoplasms 5Recurrence 5Neoplasm Metastasis 5Glioblastoma 5Colonic Neoplasms 5Brain Neoplasms 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Polycystic Ovary Syndrome 4Lymphoma, Follicular 4Fallopian Tube Neoplasms 4

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2Bevacizumab 2zimberelimab 1eribulin 1Vinorelbine 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Recurrence × Clear all
NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

NCT07286162 2026-01-27

CALM-TF

University Health Network, Toronto

Phase 3 Not yet recruiting
300 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT05810623 2023-04-12

MINERVA

Medical University of Vienna

Phase 3 Not yet recruiting
394 enrolled
Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3 Not yet recruiting
424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
368 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡